Clinical trials: COVID-19; Immunity
COVID-19, SARS-CoV-2 Infection
Immune Response to Third Dose of COVID-19 Vaccine in Solid Organ Transplant
The Coronavirus Disease 2019 (COVID-19) pandemic has claimed over 5 million lives globally. Fortunately, a substantial and growing number of SARS-CoV-2 vaccines with very high efficacy have been developed, manufactured, and…
- Conditions
- COVID-19, SARS-CoV-2 Infection, Solid Organ Transplant, Vaccine Response Impaired
- Trial name
- NCT05124509
- Testing
- Three doses of SARS-CoV-2 BNT162b2 vaccine (observational), Two doses of CoronaVac and one dose of BNT162b2 SARS-CoV-2 vaccine (observational)
- Where
- Chile
- Volunteers
- 147 people
- Sponsor
- Pontificia Universidad Catolica de Chile
Liver Diseases, Covid19
Safety and Immune Response of COVID-19 Vaccination in Patients With Chronic Liver Diseases
On 11 February 2020, the International Committee for the Classification of Viruses named the disease caused by SAＲS-CoV-2 infection in humans as the new coronavirus pneumonia (coronavirus disease 2019, COVID-19).
- Conditions
- Liver Diseases, Covid19, Adverse Reaction to Vaccine
- Trial name
- SIMPLE (NCT05007665)
- Testing
- SARS-COV-2 VACCINE
- Where
- China
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- The Second Affiliated Hospital of Chongqing Medical University
Immune Response to Covid 19 Vaccination
Comparative Study of Patterns of Immune Response to COVID 19 Vaccination
An effective vaccine stands as the most effective way for controlling the COVID 19 pandemic , yet, immunogenic vaccine efficacy needs to be extensively studied .
- Trial name
- NCT05408299
- Testing
- Covid vaccines (Moderna - Pfizer- Astra Zeneca- Johnson and Johnson - Sinopahrm)
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- National Research Centre, Egypt
COVID-19 Respiratory Infection, COVID-19 Vaccine Adverse Reaction
A Randomized, Phase I Study of DNA Vaccine OC-007 as a Booster Dose of COVID-19 Vaccine
This is a randomized, placebo-controlled, double-blinded phase I study, designed to evaluate the safety including reactogenicity and immunogenicity of this investigational DNA vaccine delivered intramuscularly by in vivo EP in…
- Trial name
- OpenCorona1 (NCT05685953)
- Testing
- DNA vaccine OC-007
- Where
- Sweden
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Matti Sällberg
Covid19, Overweight
Safety and Immune Response of COVID-19 Vaccination in Overweight People With Excessive BMI
On 11 February 2020, the International Committee for the Classification of Viruses named the disease caused by SAＲS-CoV-2 infection in humans as the new coronavirus pneumonia (coronavirus disease 2019, COVID-19).
- Trial name
- NCT05043272
- Testing
- SARS-COV-2 VACCINE
- Where
- China
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- The Second Affiliated Hospital of Chongqing Medical University
COVID-19, Influenza
Clinical Study on the Immune Response Characteristics of Novel Coronavirus and Influenza Virus Infection
This is an open-label, prospective observational study in people 18 years of age and older designed to track changes in the dynamics of the respiratory and peripheral blood immune response in people infected with influenza virus…
- Trial name
- NCT06667063
- Testing
- Nasal swab/Nasopharyngeal swab/Blood sample collection, Nasal swab/Nasopharyngeal swab/Blood draw
- Where
- 2 sites in China
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Zhongnan Hospital
Healthy Volunteers
Cohort Assessing the Immunogenicity and the Safety of the COVID-19 Vaccine Janssen in Healthy Volunteers Based on 2 Age Groups: 65 Years or Older - 55 to 65 Years. Covicompare-Janssen
In response to the COVID-19 pandemic, several vaccines (Pfizer, Moderna, Astrazeneca, Janssen) have been developed and are being administered to millions of people in France and billions around the world through massive…
- Trial name
- CoviCompare_J (NCT05037266)
- Testing
- COVID-19 Vaccine Janssen (Ad26.COV2-S)
- Where
- 10 sites in France
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Multiple Sclerosis
Covid-19 Vaccine Immune Response in Multiple Sclerosis
Coronavirus (Covid-19) has affected millions of people worldwide. Vaccines to prevent Covid-19 infection have been offered to reduce the risk of infection.
- Trial name
- CoVaR-MS (NCT05269888)
- Testing
- Blood Test 1, Blood Test 2
- Where
- United Kingdom
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- University Hospitals of North Midlands NHS Trust
COVID-19, SARS-CoV-2 Infection
Immunogenicity and Safety of a Single Dose of mRNA SARS-CoV-2 Vaccine in Chinese Adults With Hybrid Immunity
This is a multicentre post-marketing cohort study to evaluate the immunogenicity and safety of a single dose of mRNA SARS-CoV-2 vaccine SYS6006 in Chinese adults predominantly with hybrid immunity.
- Trial name
- SYS6006 (NCT07834073)
- Testing
- SYS6006
- Where
- China
- Volunteers
- 2,052 people, healthy volunteers welcome
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
Cancer, Covid19
Immunity Against Severe Acute Respiratory Syndrome Coronavirus 2 Disease (COVID-19) in the Oncology Outpatient Setting
The COVIDOUT study will prospectively investigate the serological immunity of outpatient cancer patients to evaluate the prevalence of previous severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections and…
- Conditions
- Cancer, Covid19, Immunity
- Trial name
- COVIDOUT (NCT04779346)
- Where
- Germany
- Volunteers
- 500 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Covid19, Chronic Kidney Diseases
The REnal Patients COVID-19 VACcination Immune Response (RECOVAC IR) Study
Rationale: COVID-19 is associated with severely increased morbidity and mortality in patients with severely impaired kidney function, on dialysis or alive with a kidney transplant.
- Trial name
- RECOVAC-IR (NCT04741386)
- Testing
- SARS-CoV-2 vaccination
- Where
- 4 sites in Netherlands
- Volunteers
- 854 people, healthy volunteers welcome
- Sponsor
- University Medical Center Groningen
COVID-19
Serological and PCR Testing for COVID-19
Richmond Research Institute (RRI) is applying existing and new COVID-19 PCR and antibody tests to help develop methodologies which provide fast and accurate results.
- Trial name
- NCT04404062
- Testing
- Membrane-based immunoassay kit, Quantitative antibody Tests, PCR Test
- Where
- United Kingdom
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- Richmond Research Institute